CS309491A3 - Ether acids of hydroxyalkyl quinoline and pharmaceuticals based thereon - Google Patents

Ether acids of hydroxyalkyl quinoline and pharmaceuticals based thereon Download PDF

Info

Publication number
CS309491A3
CS309491A3 CS913094A CS309491A CS309491A3 CS 309491 A3 CS309491 A3 CS 309491A3 CS 913094 A CS913094 A CS 913094A CS 309491 A CS309491 A CS 309491A CS 309491 A3 CS309491 A3 CS 309491A3
Authority
CS
Czechoslovakia
Prior art keywords
phe
cme
formula
sch
group
Prior art date
Application number
CS913094A
Other languages
Czech (cs)
English (en)
Inventor
Michel L Belley
Yves Leblanc
Marc Labelle
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Publication of CS309491A3 publication Critical patent/CS309491A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
CS913094A 1990-10-12 1991-10-11 Ether acids of hydroxyalkyl quinoline and pharmaceuticals based thereon CS309491A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59688590A 1990-10-12 1990-10-12

Publications (1)

Publication Number Publication Date
CS309491A3 true CS309491A3 (en) 1992-04-15

Family

ID=24389130

Family Applications (1)

Application Number Title Priority Date Filing Date
CS913094A CS309491A3 (en) 1990-10-12 1991-10-11 Ether acids of hydroxyalkyl quinoline and pharmaceuticals based thereon

Country Status (18)

Country Link
EP (1) EP0480708B1 (ja)
JP (1) JP2538154B2 (ja)
KR (1) KR920008005A (ja)
CN (1) CN1061594A (ja)
AT (1) ATE128969T1 (ja)
AU (1) AU639612B2 (ja)
CA (1) CA2053208C (ja)
CS (1) CS309491A3 (ja)
DE (1) DE69113735T2 (ja)
ES (1) ES2079586T3 (ja)
FI (1) FI914795A (ja)
HU (1) HUT61982A (ja)
IE (1) IE913610A1 (ja)
IL (1) IL99683A0 (ja)
MX (1) MX9101556A (ja)
NO (1) NO914003L (ja)
PT (1) PT99211B (ja)
ZA (1) ZA918115B (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506227A (en) * 1992-04-13 1996-04-09 Merck Frosst Canada, Inc. Pyridine-substituted benzyl alcohols as leukotriene antagonists
US5358955A (en) * 1992-10-30 1994-10-25 Abbott Laboratories Aryl and heteroarylmethoxyphenyl inhibitors of leukotriene biosynthesis
US5438141A (en) * 1993-05-21 1995-08-01 Merck Frosst Canada, Inc. Heteroaryl and haloaryl quinoline derivatives of cyclopropaneacetic acid as leukotriene antagonists
JPH09278653A (ja) * 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd 網膜疾患治療剤
WO1998008820A1 (fr) * 1996-08-26 1998-03-05 Yamanouchi Pharmaceutical Co., Ltd. Composes de benzenesulfone et sels de ces derniers
GB2356139A (en) * 1999-11-15 2001-05-16 Bayer Ag Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and cyanamides for the treatment of diseases
EP1958936A1 (en) * 2007-02-14 2008-08-20 Inke, S.A. Process for obtaining montelukast
KR20140108627A (ko) * 2011-07-26 2014-09-12 썬 파마 어드밴스트 리서치 컴패니 리미티드 퀴놀린-, 퀸옥살린 또는 벤조티아졸계 시스테이닐 류코트리엔 길항물질 (ltc4)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62120365A (ja) * 1985-11-16 1987-06-01 バイエル・アクチエンゲゼルシヤフト 置換ベンジルエ−テル類、その製造法および用途
IE59889B1 (en) * 1986-02-14 1994-04-20 Merck Frosst Canada Inc 2-substituted quinoline dioic acids
JPS62258369A (ja) * 1986-05-02 1987-11-10 Nippon Soda Co Ltd キナゾリノン誘導体及びその製造方法
EP0271287A3 (en) * 1986-12-11 1990-06-13 Merck Frosst Canada Inc. Quinoline dioic acids and amides
IL88433A0 (en) * 1987-11-25 1989-06-30 Merck Frosst Canada Inc Diarylstyrylquinoline diacids and pharmaceutical compositions containing them
EP0349062A1 (en) * 1988-06-27 1990-01-03 Merck Frosst Canada Inc. Quinoline ether alkanoic acid
NZ233752A (en) * 1989-05-24 1993-05-26 Merck Frosst Canada Inc Substituted quinoline derivatives, preparation and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
EP0480708A2 (en) 1992-04-15
MX9101556A (es) 1994-01-31
JP2538154B2 (ja) 1996-09-25
DE69113735D1 (de) 1995-11-16
FI914795A0 (fi) 1991-10-11
KR920008005A (ko) 1992-05-27
AU8579791A (en) 1992-04-16
EP0480708A3 (en) 1992-05-20
ATE128969T1 (de) 1995-10-15
HU913218D0 (en) 1992-01-28
NO914003D0 (no) 1991-10-11
CN1061594A (zh) 1992-06-03
DE69113735T2 (de) 1996-06-13
NO914003L (no) 1992-04-13
AU639612B2 (en) 1993-07-29
PT99211A (pt) 1992-09-30
CA2053208C (en) 2003-04-15
JPH05105664A (ja) 1993-04-27
ES2079586T3 (es) 1996-01-16
ZA918115B (en) 1992-08-26
CA2053208A1 (en) 1992-04-13
EP0480708B1 (en) 1995-10-11
FI914795A (fi) 1992-04-13
IE913610A1 (en) 1992-04-22
IL99683A0 (en) 1992-08-18
HUT61982A (en) 1993-03-29
PT99211B (pt) 1999-04-30

Similar Documents

Publication Publication Date Title
US5565473A (en) Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5270324A (en) Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
CA2053209C (en) Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5428033A (en) Saturated hydroxyalkylquinoline acids as leukotriene antagonists
CA1333714C (en) Quinoline ether alkanoic acids for use as inhibitors of leukotriene biosynthesis
US5506227A (en) Pyridine-substituted benzyl alcohols as leukotriene antagonists
US5856322A (en) Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
AU648385B2 (en) Quinoline-containing ketoacids as leukotriene antagonists
US5266568A (en) Hydroxyalkylquinoline ether acids as leukotriene antagonists
AU684884B2 (en) Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
US5232916A (en) Quinoline ether alkanoic acids
CS309491A3 (en) Ether acids of hydroxyalkyl quinoline and pharmaceuticals based thereon
WO1993021168A1 (en) Thiazole-substituted benzyl alcohols as leukotriene antagonists
US5102881A (en) Quinoline ether alkanoic acids
EP0699188A1 (en) Quinoline derivatives as leukotriene antagonists
WO1993021169A1 (en) Benzothiazole-substituted benzyl alcohols as leukotriene antagonists
US5212180A (en) Quinoline-containing ketoacids as leukotriene antagonists
NO180086B (no) Umettede hydroxyalkylkinolinsyrer som leukotrienantagonister